CIK 0001660334
- Non-accelerated filer
- Smaller reporting company
Verrica Pharmaceuticals Inc.
Sign in to watch- Ticker
- VRCA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463137900
- Phone
- +1 484-453-3300
- Business address
- 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA
- 4 Open-market sale 10% owner sold 1,000 shares at an average $8.25 ($8,248)
- 4 Open-market sale 10% owner sold 4,100 shares at an average $8.02 ($32,871)
- 4 Open-market sale 10% owner sold 12,439 shares at an average $7.35 ($91,474)
- 4 Open-market sale 10% owner sold 4,215 shares at an average $9.57 ($40,331)
- 4 Open-market buy Director bought 70,200 shares at an average $14.15 ($993,021)
- 4 Open-market buy Chief Operating Officer bought 2,500 shares at $16.52 ($41,300)
- 4 Open-market buy President and CEO bought 300 shares at $16.36 ($4,908)
- 4 Open-market buy President and CEO bought 2,505 shares at an average $15.69 ($39,310)
- 4 Open-market buy President and CEO bought 4,500 shares at $15.00 ($67,500)
- 4 Open-market buy Chief Operating Officer bought 3,000 shares at $15.00 ($45,000)
- 4 Open-market buy Chief Financial Officer bought 3,000 shares at $15.00 ($45,000)
- 4 Open-market buy Chief Commercial Officer bought 1,000 shares at $15.00 ($15,000)
- 4 Open-market buy Director bought 300,000 shares at $15.00 ($4,500,000)
- 4 Open-market buy Director bought 33,000 shares at $15.08 ($497,640)
- 4 Open-market buy 10% owner bought 1,000,000 shares at $15.00 ($15,000,000)
- 3 Insider Initial Statement of Ownership
- 4 Conversion Director acquired 394,295 shares (conversion)
- 4 Conversion Director acquired 200,734 shares (conversion)
- 4 Conversion Director acquired 9,144,317 shares (conversion)
- 4 Derivatives Options or other derivatives
Page 12 of 13 · 253 filings